KCM
NGNE icon

Kynam Capital Management’s Neurogene NGNE Stock Holding History

Kynam Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,009
Closed -$94.9K – 29
2023
Q3 		$94.9K Buy
6,009
+11
+0.2% +$162 0.02% 29
2023
Q2 		$99.6K Hold
5,998
– – 0.01% 25
2023
Q1 		$84K Sell
5,998
-40
-0.7% -$469 0.01% 34
2022
Q4 		$61.5K Buy
6,038
+20
+0.3% +$207 0.01% 30
2022
Q3 		$77K Sell
6,018
-217
-3% -$4.43K 0.02% 35
2022
Q2 		$128K Sell
6,235
-790
-11% -$19.3K 0.03% 34
2022
Q1 		$264K Sell
7,025
-325
-4% -$19K 0.09% 31
2021
Q4 		$709K Buy
+7,350
New +$895K 0.38% 29

Other funds holding NGNE

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Kynam Capital Management's NGNE Position: Q4 2023 in Review

Kynam Capital Management sold out of Neurogene (NGNE) in Q4 2023, closing a stake of 6,009 shares — an estimated $94.9K sold.

Kynam Capital Management first reported a position in NGNE in Q4 2021 and held it in 8 quarters. The position peaked at $709K in Q4 2021. 35 funds tracked by Wall St. Rank hold NGNE as of Q4 2023.

  • Kynam Capital Management reported no remaining Neurogene position as of Q4 2023 after selling out during the quarter.
  • Kynam Capital Management sold 6,009 Neurogene shares in Q4 2023, an estimated $94.9K.
  • Kynam Capital Management first reported a position in Neurogene in Q4 2021 and held it in 8 quarters.
  • Kynam Capital Management's Neurogene position peaked at $709K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Neurogene as of Q4 2023.

Based on Kynam Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.